My PCR
Create Account
Logo PCR

15 May 2024

TAVI

LANDMARK RCT - Early outcomes of a randomised non-inferiority trial comparing TAVI devices: the LANDMARK trial

Sponsored by Meril

Anchorperson: A. Baumbach
Spokeperson: P. Serruys
SHOW MORE

Summary

This session provides an overview of the early outcomes of the LANDMARK trial, a randomized non-inferiority trial comparing TAVI devices. It examines baseline characteristics, the significance of intermediate sizes according to MSCT recommendations, real-world representative cases from the LANDMARK RCT, insights from quantitative aortography and echocardiography at pre-discharge and 30 days, the treatment of conduction disturbances, and the added value of Myval THV series to daily practice.

Learning Objectives

  • To learn more about the first randomised trial that will report long-term (10 years) head-to-head outcomes to prove the non-inferiority of newer generation balloon-expandable Myval transcatheter heart valve series with commercially available contemporary TAVI devices (Sapien and Evolut transcatheter heart valve series)
  • To check 30-day composite endpoint based on the Valve Academic Research Consortium-3 consensus
Related Content
Early outcomes and predictors of success in LATAM TAVI experiences Out-of-the-box TAVI: when anatomy pushes innovation Extreme TAVI: bicuspid valves, emergency TAVI, dissections and more
Recommended for you
PCR Tokyo Valves 2025: The sooner you register, the better rate you get! Your journey through PCR London Valves 2025 starts here PCR Gulf Valves: Registrations are open!